Portal de investigación
- Inicio
- Proyectos y Estudios
- A phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML patients. (A linked-trial of the CHIP-AML22/Master protocol by the NOPHO-DB-SHIP consortium).
A phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML patients. (A linked-trial of the CHIP-AML22/Master protocol by the NOPHO-DB-SHIP consortium).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
PRINCESS MÁXIMA CENTER FOR PEDIATRIC ONCOLOGY B.V.,
Cita
A phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML patients. (A linked-trial of the CHIP-AML22/Master protocol by the NOPHO-DB-SHIP consortium). (CHIP-AML22/Quizartinib). PRINCESS MÁXIMA CENTER FOR PEDIATRIC ONCOLOGY B.V.,. 2024IP:JOSÉ MARÍA FERNÁNDEZ NAVARRO.